Information Provided By: 
Fly News Breaks for January 17, 2019
DGX
Jan 17, 2019 | 05:59 EDT
UBS analyst Kevin Caliendo started Quest Diagnostics with a Neutral rating and $90 price target.
News For DGX From the Last 2 Days
DGX
Apr 26, 2024 | 06:25 EDT
Barclays lowered the firm's price target on Labcorp (LH) to $213 from $234 and keeps an Equal Weight rating on the shares. The company's Q1 print was marked by a headline beat and "mild" guidance raise that missed the high bar set by Quest Diagnostics (DGX) earlier this week, the analyst tells investors in a research note.
DGX
Apr 25, 2024 | 05:10 EDT
DGX
Apr 24, 2024 | 09:46 EDT
DGX
Apr 24, 2024 | 09:10 EDT
DGX
Apr 24, 2024 | 06:55 EDT
UBS raised the firm's price target on Quest Diagnostics to $146 from $139 and keeps a Neutral rating on the shares. UBS is more confident that Quest can hit its margin expansion story following the Q2 print and the firm's call with management, the analyst tells investors in a research note. Labor cost trends seem to have already peaked and Covid revenues should no longer be a headwind starting 2H, while above market base volume growth continues, the firm notes.
DGX
Apr 24, 2024 | 06:43 EDT
DGX
Apr 24, 2024 | 06:24 EDT
Citi raised the firm's price target on Quest Diagnostics to $145 from $135 and keeps a Neutral rating on the shares post the Q1 report. The company increased the midpoint of its fiscal 2024 revenue target and management anticipates the rest of fiscal year to follow regular seasonality on a revenue and margin basis with a step-up into Q2, the analyst tells investors in a research note.
